Veno-occlusive disease of the liver associated with chronic myelomonocytic leukemia treated with vincristine and standard doses of cytarabine

American Journal of Hematology

Volumn 79, Issue 3, 2005, Pages 216-219

  Boula, A M ^a   Mantadakis, E ^a   Xilouri, I M ^a   Christoforidou, A V ^a   Foudoulakis, A M ^a   Samonis, George ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Chronic myelomonocytic leukemia; Cytarabine; Liver; Veno occlusive disease; Vincristine

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; VINCRISTINE; VINCRISTINE SULFATE;

AGED; ARTICLE; CASE REPORT; CHRONIC MYELOMONOCYTIC LEUKEMIA; DISEASE ASSOCIATION; HUMAN; LIVER DISEASE; MALE; NEUROTOXICITY; PERONEUS NERVE PARALYSIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; VEIN OCCLUSION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DISEASE PROGRESSION; FATAL OUTCOME; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; HYPOALBUMINEMIA; KIDNEY FAILURE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; PARESIS; THROMBOCYTOPENIA; VINCRISTINE;

EID: 22044450483     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20338     Document Type: Article

References (19)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
2. nd edition. Oxford: Blackwell Science; 1999. p 113-142.
3. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Hematol J 2000;1:53-66.
4. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson M, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukaemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1302-1311.
5. Baron F, Deprez M, Beguin Y. The veno-occlusive disease of the liver. Haematologica 1997;82:718-725.
6. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995;85:3005-3020.
7. Kumar S, DeLeve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 2003;78: 589-598.
8. Ridker PM, McDermott WV. Comfrey herb tea and hepatic veno-occlusive disease. Lancet 1989;1:657-658.
9. Gill RA, Onstad GR, Cardamone JM, Maneval DC, Sumner HW. Hepatic veno-occlusive disease caused by 6-thioguanine. Ann Intern Med 1982;96:58-60.
10. Kao NL, Rosenblate HJ. 6-Thioguanine therapy for psoriasis causing toxic hepatic venoocclusive disease. J Am Acad Dermatol 1993;28:1017-1018.
11. Salat C, Holler E, Miller E, Pihusch R, Kolb HJ. Hepatic veno-occlusive disease following peripheral blood stem cell or bone marrow transplantation. Haematologica 1999;84(Suppl EHA-4): 40-43.
12. Merino JM, Casanova F, Saez-Royuela F, Velasco A, Gonzalez JB. Veno-occlusive disease of the liver associated with thiopurines in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2000;17:429-443.
13. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993;118:255-267.
14. th edition. New York: McGraw Hill; 2001. p 185-200.
15. Ortega JA, Donaldson SS, Ivy SP, Pappo A, Maurer HM. Veno-occlusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Childrens Cancer Group, the Pediatric Oncology Group, and the Pediatric Intergroup Statistical Center. Cancer 1997;79:2435-2439.
16. Green DM, Finklestein JZ, Norkool P, D'Angio GJ. Severe hepatic toxicity after treatment with single-dose dactinomycin and vincristine. A report of the National Wilms' Tumor Study. Cancer 1988;62:270-273.
17. Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic veno-occlusive disease in patients who have not received stem-cell transplantation. Cancer 2001;92:406-413.
18. Frickhofen N, Wiesneth M, Jainta C, et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994;83: 1998-2004.
19. Singbartl G. Adverse events of erythropoietin in long-term and in acute/short-term treatment. Clin Invest 1994;72: S36-S43.